34171-37-4

Basic information

• Product Name: 5-ETHYL-2-THIOURACIL
• Synonyms: 5-ETHYL-2-THIOURACIL;5-Ethyl-2-thiouracil ,98%;5-ethyl-2-sulfanylidene-1,2,3,4-tetrahydropyriMidin-4-one;5-Ethyl-2-thioxo-2,3-dihydropyriMidin-4(1H)-one
• CAS NO: 34171-37-4
• Molecular Formula: C₆H₈N₂OS
• Molecular Weight: 156.21
• Mol File: 34171-37-4.mol

Chemical Properties

• Melting Point: 191-193℃
• Appearance: /
• Storage Temp.: 2-8°C
• Solubility: DMSO (Slightly), Ethyl Acetate (Slightly), Methanol (Slightly)
• CAS DataBase Reference: 5-ETHYL-2-THIOURACIL(CAS DataBase Reference)
• NIST Chemistry Reference: 5-ETHYL-2-THIOURACIL(34171-37-4)
• EPA Substance Registry System: 5-ETHYL-2-THIOURACIL(34171-37-4)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 34171-37-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-Ethyl-2-thiouracil is used as a reactant for the synthesis of compounds with potential therapeutic applications. Its ability to inhibit the replication of the Hepatitis B virus (HBV) makes it a valuable component in the development of antiviral medications.
Used in Antiviral Applications:
In the field of virology, 5-Ethyl-2-thiouracil is employed as an inhibitor of Hepatitis B virus (HBV) replication. By targeting the viral replication process, it can help in the development of treatments for HBV infections, which can lead to chronic liver diseases and liver cancer.
Used in Chemical Synthesis:
As a versatile reactant, 5-Ethyl-2-thiouracil is utilized in the synthesis of various compounds for different industries, including pharmaceuticals, agrochemicals, and materials science. Its unique chemical properties allow it to be a key component in the creation of new molecules with specific functions and applications.

Upstream product

• 30150-54-0 5-ethyl-2-methylsulfanyl-3H-pyrimidin-4-one 
• 107-31-3 Methyl formate 
• 623-42-7 butanoic acid methyl ester 
• 124-41-4 sodium methylate 
• 105-54-4 butanoic acid ethyl ester 
• 109-94-4 formic acid ethyl ester 
• 17356-08-0 thiourea 
• 63857-18-1 2-formyl-butyric acid methyl ester 
• 62142-16-9 ethyl (2Z)-2-ethyl-3-hydroxy-2-propenoate 

Downstream Products

• 4212-49-1 5-ethyluracil 
• 30150-54-0 5-ethyl-2-methylsulfanyl-3H-pyrimidin-4-one 
• 25198-98-5 5-ethyl-4(3H)-pyrimidinone 
• 172255-78-6 5-ethyl-1-[(2-hydroxyethoxy)methyl]-6-[(3-methylphenyl)selenenyl]-2-thiouracil 
• 1026372-53-1 1-[2-(tert-Butyl-dimethyl-silanyloxy)-ethoxymethyl]-5-ethyl-2-thioxo-6-m-tolylselanyl-2,3-dihydro-1H-pyrimidin-4-one 
• 1026558-44-0 1-[2-(tert-Butyl-dimethyl-silanyloxy)-ethoxymethyl]-6-(3,5-dimethyl-phenylselanyl)-5-ethyl-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one 
• 132774-45-9 5-ethyl-1-(ethoxymethyl)-6-(phenylthio)uracil 
• 132774-46-0 5-ethyl-1-<(benzyloxy)methyl>-6-(phenylthio)uracil 
• 136011-43-3 5-ethyl-1-ethoxymethyl-6-(phenylthio)-2-thiouracil 
• 136160-38-8 5-Ethyl-1-isopropoxymethyl-6-phenylsulfanyl-1H-pyrimidine-2,4-dione 
• 136160-39-9 5-Ethyl-1-isopropoxymethyl-6-phenylsulfanyl-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one 
• 136011-44-4 5-ethyl-1-ethoxymethyl-6-(3,5-dimethylphenylthio)uracil 
• 136011-45-5 5-ethyl-1-ethoxymethyl-6-(3,5-dimethylphenylthio)-2-thiouracil 
• 136160-24-2 5-ethyl-1-benzyloxymethyl-6-(phenylthio)-2-thiouracil 

Relevant articles and documents

Original 2-(3-alkoxy-1 H -pyrazol-1-yl)pyrimidine derivatives as inhibitors of human dihydroorotate dehydrogenase (DHODH)

From a research program aimed at the design of new chemical entities followed by extensive screening on various models of infectious diseases, an original series of 2-(3-alkoxy-1H-pyrazol-1-yl)pyrimidines endowed with notable antiviral properties were found. Using a whole cell measles virus replication assay, we describe here some aspects of the iterative process that, from 2-(4-benzyl-3-ethoxy-5-methyl-1H-pyrazol-1-yl)pyrimidine, led to 2-(4-(2,6-difluorophenoxy)-3-isopropoxy-5-methyl-1H-pyrazol-1-yl)-5-ethylpyrimidine and a 4000-fold improvement of antiviral activity with a subnanomolar level of inhibition. Moreover, recent precedents in the literature describing antiviral derivatives acting at the level of the de novo pyrimidine biosynthetic pathway led us to determine that the mode of action of this series is based on the inhibition of the cellular dihydroorotate dehydrogenase (DHODH), the fourth enzyme of this pathway. Biochemical studies with recombinant human DHODH led us to measure IC50 as low as 13 nM for the best example of this original series when using 2,3-dimethoxy-5-methyl-6-(3-methyl-2-butenyl)-1,4-benzoquinone (coenzyme Q1) as a surrogate for coenzyme Q10, the cofactor of this enzyme.

PYRAZOLE DERIVATIVES AS DIHYDROOROTATE DEHYDROGENASE (DHODH) INHIBITORS

The present invention relates to compounds of formula (I) for their use in the treatment and/or prevention of auto-immune or auto-immune related diseases, cancer, viral infections, and central nervous system diseases and disorders, by inhibiting human deh

Synthesis and structure-activity relationships of a novel series of pyrimidines as potent inhibitors of TBK1/IKKε kinases

The design, synthesis and structure-activity relationships of a novel series of 2,4-diamino-5-cyclopropyl pyrimidines is described. Starting from BX795, originally reported to be a potent inhibitor of PDK1, we have developed compounds with improved selectivity and drug-like properties. These compounds have been evaluated in a range of cellular and in vivo assays, enabling us to probe the putative role of the TBK1/IKKε pathway in inflammatory diseases.

PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP - PLA2

The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema (I).